The online version of this article (doi:10.1186/s12883-017-0913-3) contains supplementary material, which is available to authorized users.
Evidence on the use of fingolimod in real-world clinical practice and data on patient-reported health-related quality of life (HRQoL) in countries such as the Middle East are sparse. The Prospective Evaluation of Treatment with Fingolimod for Multiple Sclerosis (PERFORMS) study assessed HRQoL and effectiveness and safety of fingolimod in patients with relapsing-remitting multiples sclerosis (RRMS), primarily in Middle Eastern countries.
This 12-month, observational, multicentre, prospective, real-world study was conducted in patients with RRMS who initiated fingolimod or another approved disease-modifying treatment (DMT) within 4 weeks before study entry. Patients were enrolled in a 2:1 ratio to obtain more data in fingolimod and parallel in other DMTs cohort by physicians during routine medical care. Key study outcomes included HRQoL assessed using MS International QoL (MusiQoL), MS relapses and disability. Safety was assessed throughout the study period. Due to the observational nature of the study, no neuroimaging assessments were mandated and central reading was not performed.
Of 249 enrolled patients, 247 were included in the analysis (fingolimod cohort 172; other DMTs cohort 75). Overall, the mean age of patients was 36.5 years, 64.4% were women and ~90% were Caucasians. At baseline, mean MS duration since diagnosis was 7.2 years in the fingolimod and 4.8 years in the other DMTs cohorts. Overall, mean changes in MusiQoL index scores were −2.1 in the fingolimod cohort and −0.7 in the other DMTs cohort at Month 12, but improvement was not significant vs. baseline in both cohorts. Proportion of relapse-free patients increased significantly during the study vs. 0–12 months before the study in the fingolimod cohort (80.2% vs. 24.4%; p < 0.0001). Proportion of patients free from disability progression was 86.5% in the fingolimod cohort. The incidences of AEs were 59.9% and 50.6% in the fingolimod and other DMTs cohorts, respectively. First-dose monitoring of fingolimod observed no cases of symptomatic bradyarrhythmia. Three cases of bradycardia were reported in the fingolimod cohort: one after the first dose and two during the study. No cases of macular oedema were observed during the study.
Fingolimod treatment maintained QoL over 12 months and was effective in reducing relapse rate and disability progression. No new safety findings were observed in this real-world observational study in Middle Eastern countries.
Multiple Sclerosis International Federation. Atlas of MS 2013. http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf. Accessed 30 June 2015.
Inshasi J, Thakre M. Prevalence of multiple sclerosis in Dubai. United Arab Emirates Int J Neurosci. 2011;121:393–8. PubMed
O’Connor PW, Oh J. Disease modifying agents in multiple sclerosis. Handb Clin Neurol. 2014:465–501.
Coustans M, Debouverie M, Kobelt G, Lebrun-Frenay C, Leray E, Papeix C, et al. Long-term efficacy, safety, tolerability and quality of life with fingolimod treatment in patients with multiple sclerosis in real-world settings in France: VIRGILE study design. Poster presented at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis 7–10 October 2015, Barcelona, Spain. http://onlinelibrary.ectrims-congress.eu/ectrims/2015/31st/115257/bashar.allaf.long-term.efficacy.safety.tolerability.and.quality.of.life.with.html?f=m1. Accessed 4 November 2016.
Kuperman G. Interim analysis II from REAL study: quality of life and persistence with fingolimod treatment in relapsing remitting multiple sclerosis patients in Argentina. Neurology. 2015;84:255.
Crayton H, Hunter SF. Huffman C et al. CMSC ACTRIMS: Improved quality of life after therapy change to fingolimod; 2013. https://cmsc.confex.com/cmsc/2013/webprogram/Paper1313.html. Accessed 9 November 2016
Czaplinski A, Jaquiery E, Stellmes P, Ramseier S, Baumann A, Kurlandchikov O, et al. Interim Results of the Swiss Post Marketing Surveillance Monitoring Quality of Life and Treatment Satisfaction in Patients With Relapsing-Remitting Multiple Sclerosis. Neurology. 2014;82(Supplement 10):179.
Miller D, Lee J, Hashmonay R, Agashivala N, Rudick R. Patient disability and quality of life after fingolimod initiation: the Cleveland Clinic experience. Neurology. 2013;34452
Fox E, Edwards K, Burch G, Wynn DR, LaGanke C, Crayton H, et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the randomized, open-label, multicenter, evaluate patient OutComes (EPOC) study in relapsing multiple sclerosis. Mult Scler Relat Disord. 2014;3:607–19. CrossRefPubMed
Inshasi JS, Sarathchandran P, Alboudi A, Kamal Y. Fingolimod treatment in relapsing-remitting multiple sclerosis—the real-world experience at Rashid Hospital multiple sclerosis (MS) center in Dubai. Mult Scler J. 2016;10 doi: 10.1177/1352458516635979.
Ziemssen T, Schwarz HJ, Fuchs A, Cornelissen C. 36 month PANGAEA: a 5-year non-interventional study of safety, efficacy and pharmacoeconomic data for fingolimod patients in daily clinical practice. Neurology. 2015;84(Suppl 14):251.
Simeoni M, Auquier P, Fernandez O, Flachenecker P, Stecchi S, Constantinescu C, et al, MusiQol study group. Validation of the Multiple Sclerosis International Quality of Life questionnaire. Mult Scler. 2008;14:219–230.
Al-Tahan AM, Al-Jumah MA, Bohlega SM, Al-Shammari SN, Al-Sharoqi IA, Dahdaleh MP, et al. The importance of quality-of-life assessment in the management of patients with multiple sclerosis. Recommendations from the Middle East MS advisory group. Neurosciences (Riyadh). 2011;16:109–13.
Guy W. ECDEU Assessment Manual for Psychopharmacology—Revised (DHEW Publ No ADM 76–338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976. p. 218–22.
Kurzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–52. CrossRef
WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. Updated on October 2013. https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/. Accessed 12 July 2017.
- Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East
- BioMed Central